Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash Flows From Operating Activities    
Net loss $ (11,214) $ (18,308)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 4,350 4,102
Interest accretion expense 375 414
Reversal of 2019 bonus accrual (1,156)
Bad debt (recovery) expense (140) 250
Mark to market on warrants 137 (62)
Stock-based compensation 1,228 1,354
Amortization of deferred financing fees 110
Accrued interest - Related Parties 372
ESPP expense 86 27
Change in fair value of contingent consideration (57)
Gain on DiamiR transaction (235)
Other gains and expenses, net (2)
Other changes in operating assets and liabilities:    
Decrease in accounts receivable 1,788 1,625
Increase in other current assets (413) (898)
Increase in other long-term assets (14)
Decrease in accounts payable (2,084) (1,319)
(Decrease) increase in accrued salaries and bonus (433) 129
(Decrease) increase in accrued liabilities (1,349) 1,472
Decrease in long-term liabilities (6) (25)
Net cash used in operating activities (7,501) (12,395)
Cash Flows From Investing Activities    
Purchase of property and equipment (192) (1,275)
Sale of property and equipment 39
Net cash used in investing activities (153) (1,275)
Cash Flows From Financing Activities    
Issuance of common stock, net of expenses 335 434
Issuance of Series B preferred stock, net of expenses 19,223
Loan proceeds - related parties 7,500
Deferred financing fees (123)
Payments on line of credit (3,000)
Net cash provided by financing activities 7,712 16,657
Net increase in cash, cash equivalents and restricted cash 58 2,987
Cash, cash equivalents and restricted cash – beginning 3,372 2,321
Cash, cash equivalents and restricted cash – ending $ 3,430 $ 5,308